Search Results - "Cohan, Stanley L."

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis by Cohan, Stanley L, Lucassen, Elisabeth B, Romba, Meghan C, Linch, Stefanie N

“…Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade…”
Get full text

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis by Cohan, Stanley L., Benedict, Ralph H. B., Cree, Bruce A. C., DeLuca, John, Hua, Le H., Chun, Jerold

“…Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P 1 ) and 5 (S1P 5 ) modulator approved in the United States and the European Union as…”
Get full text

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex) by Cohan, Stanley L., Hendin, Barry A., Reder, Anthony T., Smoot, Kyle, Avila, Robin, Mendoza, Jason P., Weinstock-Guttman, Bianca

“…Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS)…”
Get full text

Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses by Williams, Mitzi J, Amezcua, Lilyana, Cohan, Stanley L, Cohen, Jeffrey A, Delgado, Silvia R, Hua, Le H, Lucassen, Elisabeth B, Piccolo, Rebecca S, Koulouris, Chloe R, Stankiewicz, James

“…Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse…”
Get full text

Advancing Care and Outcomes for African American Patients With Multiple Sclerosis by Okai, Annette F., Howard, Annette M., Williams, Mitzi J., Brink, Justine D., Chen, Chiayi, Stuchiner, Tamela L., Baraban, Elizabeth, Jeong, Grace, Cohan, Stanley L.

“…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
Get full text

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety by Fox, Robert J., Kita, Mariko, Cohan, Stanley L., Henson, Lily Jung, Zambrano, Javier, Scannevin, Robert H., O'Gorman, John, Novas, Mark, Dawson, Katherine T., Phillips, J. Theodore

“…Abstract Background: Multiple sclerosis (MS) is a chronic inflammatory disease, affecting more than 2.5 million people worldwide with more 400,000 cases in the…”
Get full text

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY) by Cohan, Stanley L., Moses, Harold, Calkwood, Jonathan, Tornatore, Carlo, LaGanke, Chris, Smoot, Kyle E., Meka, Venkata, Okwuokenye, Macaulay, Hotermans, Christophe, Mendoza, Jason P., Mann, Monica K., Meltzer, Leslie A.

“…Delayed-release dimethyl fumarate (DMF) may be a therapeutic option for patients with relapsing-remitting multiple sclerosis (RRMS) who are treated with…”
Get full text

Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study by Benedict, Ralph H B, Vo, Pamela, Adlard, Nicholas, Grennan, Olwyn, Enstone, Ashley, Bridge, Daisy, Wyn, Robin, Cohan, Stanley L

“…Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS). Utility values…”
Get full text

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND by Repovic, Pavle, Robertson, Derrick, Kresa-Reahl, Kiren, Cohan, Stanley L., Su, Ray, Avila, Robin, Koulinska, Irene, Mendoza, Jason P.

“…Introduction This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing…”
Get full text

Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study by Hua, Le H, Bar-Or, Amit, Cohan, Stanley L, Lublin, Fred D, Coyle, Patricia K, Cree, Bruce AC, Meng, Xiangyi, Su, Wendy, Cox, Gina Mavrikis, Fox, Robert J

“…Older age and longer disease duration (DD) may impact the effectiveness of disease-modifying therapies in patients with multiple sclerosis (MS). Siponimod is a…”
Get full text

Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis by YEPES, M, SANDKVIST, M, WONG, M. K. K, COLEMAN, T. A, SMITH, E, COHAN, S. L, LAWRENCE, D. A

“…Neuroserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily localized to neurons within the central nervous system,…”
Get full text

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy by Cohan, Stanley L, Edwards, Keith, Lucas, Lindsay, Gervasi-Follmar, Tiffany, O’Connor, Judy, Siuta, Jessica, Kamath, Vineetha, Garten, Lore, Chen, Chiayi, Thomas, James, Smoot, Kyle, Kresa-Reahl, Kiren, Spinelli, Kateri J

“…Background Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study (4649) by Cohan, Stanley L., Bar-Or, Amit, Coyle, Patricia K., Lublin, Fred D., Meng, Xiangyi, Su, Wendy, Cree, Bruce A. C.

“…Abstract only…”
Get full text

Advancing Care and Outcomes for African American Patients With Multiple Sclerosis by Okai, Annette F., Howard, Annette M., Williams, Mitzi J., Brink, Justine D., Chen, Chiayi, Stuchiner, Tamela L., Baraban, Elizabeth, Jeong, Grace, Cohan, Stanley L.

“…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
Get full text

Safety and Tolerability of Conversion to Siponimod in Patients with Relapsing Multiple Sclerosis: Interim Results of the EXCHANGE Study (4598) by Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cox, Gina, Cruz, Linda-Ali, Meng, Xiangyi, Su, Wendy, Cohan, Stanley L.

“…Abstract only…”
Get full text

Disutility of Cognitive Processing Speed by Adlard, Nicholas, Enstone, Ashley, Vo, Pamela, Bridge, Daisy, Wyn, Robin, Benedict, Ralph H.B, Grennan, Olwyn, Cohan, Stanley L

“…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
Get full text

Disutility of Cognitive Processing Speed Elicitation Study by Benedict, Ralph H.B, Vo, Pamela, Adlard, Nicholas, Grennan, Olwyn, Enstone, Ashley, Bridge, Daisy, Wyn, Robin, Cohan, Stanley L

“…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
Get full text

Effect of Siponimod on Disability in EXPAND Re-examined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS (4051) by Cutter, Gary, Meng, Xiangyi, Bar-Or, Amit, Benedict, Ralph H.B., Cohan, Stanley L., Jaitly, Nina, Su, Wendy, Tomic, Davorka, Cree, Bruce A.C.

“…Abstract only…”
Get full text

2271 Safety and tolerability of conversion to siponimod with and without titration in patients with relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study by Simpson, Marion, Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cruz, Linda-Ali, Cox, Gina Mavrikis, Cohan, Stanley L

“…ObjectivesEXCHANGE is a 6-month, open-label, single-arm trial of conversion to siponimod in patients with MS. Here we report interim analyses evaluating safety…”
Get full text